(Circulation. 1996;93:1328-1330.)
© 1996 American Heart Association, Inc.
Articles |
Inducible Carboxypeptidase Activity
A Role in Clot Lysis In Vivo
From the Joseph J. Jacobs Center for Thrombosis and Vascular Biology, The Cleveland (Ohio) Clinic Foundation.
Correspondence to Edward F. Plow, PhD, Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Department of Molecular Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Ave (FF20), Cleveland, OH 44195. E-mail plowe@cesmtp.ccf.org.
Background An inducible carboxypeptidase activity in human plasma delays tissue-type plasminogen activator (TPA)–induced clot lysis in vitro. We investigated whether carboxypeptidase activity is induced in vivo during thrombosis and thrombolytic therapy in a canine model of myocardial infarction.
Methods and Results By use of synthetic substrate assays, dog plasma was shown to contain an inducible carboxypeptidase activity that is efficiently inhibited by potato carboxypeptidase inhibitor. This inhibitor accelerates TPA-mediated clot lysis in vitro by an average of 27% (n=5, P=.046). Analysis of the inducible carboxypeptidase activity in plasma samples of dogs with electrically induced thrombosis of the circumflex coronary artery treated with TPA revealed that (1) inducible carboxypeptidase activity is increased during thrombosis (8.7±2.0 U/L, P<.013) and thrombolytic therapy (9.9±1.8 U/L, P<.024) compared with baseline (3.2±2.0 U/L); (2) thrombosis is a prerequisite of carboxypeptidase induction during and after TPA infusion, since carboxypeptidase levels were lower in dogs without a coronary thrombus; and (3) a significant positive correlation (r=.6, P<.0069) of carboxypeptidase activity with time to restoration of blood flow was observed.
Conclusions These data indicate that carboxypeptidase activity is induced in vivo and may influence thrombolysis.
Key Words: carboxypeptidase • plasminogen activators • thrombosis • thrombolysis
This article has been cited by other articles:
 |
|
 |
|
  M. E. Meltzer, C. J.M. Doggen, P. G. de Groot, J. C.M. Meijers, F. R. Rosendaal, and T. Lisman Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men Haematologica, June 1, 2009; 94(6): 811 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Anand, I. Pallares, Z. Valnickova, T. Christensen, J. Vendrell, K. U. Wendt, H. A. Schreuder, J. J. Enghild, and F. X. Aviles The Crystal Structure of Thrombin-activable Fibrinolysis Inhibitor (TAFI) Provides the Structural Basis for Its Intrinsic Activity and the Short Half-life of TAFIa J. Biol. Chem., October 24, 2008; 283(43): 29416 - 29423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Weitz, J. Hirsh, and M. M. Samama New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 234S - 256S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Weitz, J. Hirsh, and M. M. Samama New Anticoagulant Drugs: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 265S - 286S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nesheim Thrombin and Fibrinolysis Chest, September 1, 2003; 124 (2009): 33S - 39S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Schatteman, F. Goossens, J. Leurs, R. Verkerk, S. Scharpe, J. J. Michiels, and D. Hendriks arboxypeptidase U at the Interface Between Coagulation and Fibrinolysis Clinical and Applied Thrombosis/Hemostasis, April 1, 2001; 7(2): 93 - 101. [Abstract] [PDF]
|
|
|
|
|
|
J. I. Weitz and J. Hirsh New Anticoagulant Drugs Chest, January 1, 2001; 119 (2009): 95S - 107S. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bajzar Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway Arterioscler Thromb Vasc Biol, December 1, 2000; 20(12): 2511 - 2518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Juhan-Vague, J. F. Renucci, M. Grimaux, P. E. Morange, J. Gouvernet, Y. Gourmelin, and M. C. Alessi Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors Arterioscler Thromb Vasc Biol, September 1, 2000; 20(9): 2156 - 2161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Boffa, R. Bell, W. K. Stevens, and M. E. Nesheim Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor J. Biol. Chem., April 21, 2000; 275(17): 12868 - 12878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Ansell, J. I. Weitz, and A. J. Comerota Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism Hematology, January 1, 2000; 2000(1): 266 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Klement, P. Liao, and L. Bajzar A Novel Approach to Arterial Thrombolysis Blood, October 15, 1999; 94(8): 2735 - 2743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Schatteman, F. J. Goossens, S. S. Scharpe, H. M. Neels, and D. F. Hendriks Assay of Procarboxypeptidase U, a Novel Determinant of the Fibrinolytic Cascade, in Human Plasma Clin. Chem., June 1, 1999; 45(6): 807 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, M. B. Boffa, L. Bajzar, J. B. Walker, and M. E. Nesheim A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor J. Biol. Chem., October 16, 1998; 273(42): 27176 - 27181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Boffa, W. Wang, L. Bajzar, and M. E. Nesheim Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties J. Biol. Chem., January 23, 1998; 273(4): 2127 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Topol Toward a New Frontier in Myocardial Reperfusion Therapy : Emerging Platelet Preeminence Circulation, January 20, 1998; 97(2): 211 - 218. [Full Text] [PDF]
|
|
|
|
|
|
D. V. Sakharov, E. F. Plow, and D. C. Rijken On the Mechanism of the Antifibrinolytic Activity of Plasma Carboxypeptidase B J. Biol. Chem., May 30, 1997; 272(22): 14477 - 14482. [Abstract] [Full Text] [PDF]
|
|